IN2015KN00571A - - Google Patents

Info

Publication number
IN2015KN00571A
IN2015KN00571A IN571KON2015A IN2015KN00571A IN 2015KN00571 A IN2015KN00571 A IN 2015KN00571A IN 571KON2015 A IN571KON2015 A IN 571KON2015A IN 2015KN00571 A IN2015KN00571 A IN 2015KN00571A
Authority
IN
India
Prior art keywords
vascular
present disclosure
ntprocnp
finding
subject
Prior art date
Application number
Other languages
English (en)
Inventor
Eric Arnold Espiner
Timothy Charles Ramsey Prickett
Original Assignee
Otago Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otago Innovation Ltd filed Critical Otago Innovation Ltd
Publication of IN2015KN00571A publication Critical patent/IN2015KN00571A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN571KON2015 2012-08-13 2013-08-13 IN2015KN00571A (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261682729P 2012-08-13 2012-08-13
PCT/NZ2013/000142 WO2014027899A1 (en) 2012-08-13 2013-08-13 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Publications (1)

Publication Number Publication Date
IN2015KN00571A true IN2015KN00571A (https=) 2015-07-17

Family

ID=50101335

Family Applications (1)

Application Number Title Priority Date Filing Date
IN571KON2015 IN2015KN00571A (https=) 2012-08-13 2013-08-13

Country Status (9)

Country Link
US (1) US10012656B2 (https=)
EP (1) EP2883060B1 (https=)
JP (1) JP6423788B2 (https=)
CN (1) CN104937420B (https=)
AU (1) AU2013303302B2 (https=)
CA (1) CA2882116A1 (https=)
IN (1) IN2015KN00571A (https=)
SG (2) SG11201501145SA (https=)
WO (1) WO2014027899A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
JP6423788B2 (ja) * 2012-08-13 2018-11-14 オタゴ イノベーション リミテッド 血管障害及び妊娠合併症のバイオマーカーとしてのＮＴ−ｐｒｏＣＮＰ
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2016064815A1 (en) * 2014-10-20 2016-04-28 Massachusetts Institute Of Technology Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
TWI776812B (zh) * 2016-06-02 2022-09-11 荷蘭商菲林公司 血管收縮素-1-受體拮抗劑
WO2018216580A1 (ja) * 2017-05-22 2018-11-29 東ソー株式会社 アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬
WO2019199869A1 (en) * 2018-04-10 2019-10-17 Quanterix Corporation Quantification of biomarkers present in physiological samples

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT407580B (de) * 1999-08-20 2001-04-25 Biomedica Gmbh Indikatorpeptid zur diagnose und/oder vorhersage von cardiovasculären und/oder endothelialen erkrankungen, antikörperzusammensetzung und immunoassay
WO2004099139A1 (en) 2000-09-15 2004-11-18 Baylor University Indole-containing compounds with anti-tubulin and vascular targeting activity
DK1644740T3 (da) * 2003-06-17 2011-02-21 Otago Innovation Ltd Vurdering af skeletal vækst ved anvendelse af målinger af NT-CNP-peptider
DE10338733A1 (de) 2003-08-22 2005-03-24 Berdel, Wolfgang E., Prof. Dr.med. Fusionspolypeptide und deren Verwendung für die antivaskuläre Tumortherapie
US20100041989A1 (en) 2006-09-29 2010-02-18 The Trustees Of The University Of Pennsylvania Use of ultrasound as an antivascular agent
CN103109192A (zh) * 2010-06-18 2013-05-15 塞尚公司 用于妊娠性高血压和先兆子痫的预后和风险评估的标志物
US20150293119A1 (en) 2011-12-23 2015-10-15 Mayo Foundation For Medical Education And Research Assessing renal structural alterations and outcomes
JP6423788B2 (ja) * 2012-08-13 2018-11-14 オタゴ イノベーション リミテッド 血管障害及び妊娠合併症のバイオマーカーとしてのＮＴ−ｐｒｏＣＮＰ

Also Published As

Publication number Publication date
JP2015526725A (ja) 2015-09-10
US10012656B2 (en) 2018-07-03
EP2883060B1 (en) 2018-03-21
US20150241451A1 (en) 2015-08-27
CN104937420B (zh) 2018-07-03
CA2882116A1 (en) 2014-02-20
WO2014027899A1 (en) 2014-02-20
EP2883060A4 (en) 2016-06-29
EP2883060A1 (en) 2015-06-17
SG11201501145SA (en) 2015-04-29
AU2013303302B2 (en) 2017-10-12
CN104937420A (zh) 2015-09-23
SG10201700872TA (en) 2017-04-27
JP6423788B2 (ja) 2018-11-14
AU2013303302A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
IN2015KN00571A (https=)
PH12018500513A1 (en) Methods for diagnosing and evaluating non-alcoholic steatohepatitis
BR112017011172A2 (pt) atenuação de interferência para sinais de referência de posicionamento
MX2016013635A (es) Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes.
TN2016000553A1 (en) Methods and compositions for treating ulcers
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
HK1218576A1 (zh) 结核病生物标志物及其用途
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
WO2017031067A3 (en) Biomarkers for treatment of alopecia areata
MX2018001759A (es) Tratamiento acido para fertilizantes para incrementar al solubilidad y disponibilidad del zinc.
BR112015030293A2 (pt) compensação de dados magnéticos para inspeções de mapeamento de veículo submarino autônomo
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
BR112015017767A2 (pt) sistema para detectar estágios do sono de um indivíduo, método para detectar estágios do sono de um indivíduo, e, sistema configurado para detectar estágios do sono de um indivíduo
MX2015014847A (es) Pronostico medico y prediccion de la respuesta al tratamiento utilizando multiples actividades de la trayectoria de señalizacion celular.
BR112018001260A2 (pt) mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição.
WO2011047033A3 (en) Biomarker for identification of melanoma tumor cells
WO2012101511A3 (en) System, method and device for automatic and autonomous determination of hemodynamic and cardiac parameters using ultrasound
WO2013023048A3 (en) Synergistic interaction of weak cation exchange resin and magnesium oxide
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
MX2024001909A (es) Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.
BR112017011642A2 (pt) composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+.
MX2014013079A (es) Metodo in vitro para el diagnostico y vigilancia del cancer.
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
WO2017027391A3 (en) Genetic abnormalities in plasma cell dyscrasias